This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Danaher’s purchase of GE Healthcare biopharma unit wins conditional antitrust clearance in China (English version)

By MLex Staff ( March 25, 2020, 01:55 GMT | Insight) -- US medical equipment maker Danaher’s acquisition of the biopharma business of GE Healthcare Life Sciences was approved by China’s State Administration for Market Regulation on condition that the acquirer divest itself of certain business units to ease the regulator’s antitrust concerns. MLex provides an English translation of the decision.Below is an English translation of the decision, provided by MLex. The original decision in Chinese can be found here....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login